Article
Biochemistry & Molecular Biology
Luhao Li, Suxin Li, Haohao Wang, Lin Li, Peiju Wang, Dongqi Shen, Xiaowei Dang
Summary: The study revealed that GSG2 is overexpressed in HCC tissues, and knockdown of GSG2 can inhibit the progression of HCC, promote cell apoptosis, and potentially participate in the oncogenesis of HCC.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Oncology
Chun-Ming Li, Jie Zhang, Wu Wu, Zhu Zhu, Feng Li, Di Wu, Xiao-Jun Wang, Chuan-Ming Xie, Jian-Ping Gong
Summary: This study investigated the biological function and potential mechanism of FBXO43 in hepatocellular carcinoma (HCC). The results showed that FBXO43 was upregulated in HCC patient tissues and correlated with poor clinicopathological features. Knockdown of FBXO43 inhibited HCC cell proliferation, migration, and epithelial-mesenchymal transition (EMT), which was mediated by its interaction with cyclin D1 (CCND1) and promotion of CCND1 stability. Targeting the FBXO43-CCND1 axis may provide a new potential strategy for HCC treatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Federica Ragusa, Nadia Panera, Silvia Cardarelli, Marco Scarsella, Marzia Bianchi, Stefano Biagioni, Mauro Giorgi, Anna Alisi, Mara Massimi
Summary: The study found that PDE4D gene/protein were over-expressed in HCC samples compared to normal livers, and silencing or pharmacological inhibition of PDE4D activity showed anti-tumorigenic effects by reducing cell proliferation and increasing apoptosis. Over-expression of PDE4D in human HCCs correlated with up-regulated pro-oncogenic genes, suggesting a new potential molecular network for further investigation. PDE4D depletion/inhibition may serve as a novel biomarker for diagnosis and a potential adjuvant target for HCC therapy.
Article
Cell Biology
Xiao-Wei Dang, Qi Pan, Zhen-Hai Lin, Hao-Hao Wang, Lu-Hao Li, Lin Li, Dong-Qi Shen, Pei-Ju Wang
Summary: This study confirmed that DEPDC1B knockdown restricts tumor growth in vitro and in vivo, and it interacts with CDK1, being a potential therapeutic target involved in HCC growth and progression. The results suggest that DEPDC1B plays a key role in HCC and may be a promising target for therapeutic interventions.
Article
Biochemistry & Molecular Biology
Manal Alfwuaires, Hany Elsawy, Azza Sedky
Summary: This study suggests that ACN can inhibit the activation of STAT3 and suppress the expression of genes associated with HCC, making it a promising therapeutic compound for the treatment of HCC and other cancers.
Article
Oncology
Yan-hui Wu, Bin Yu, Jiang-min Zhou, Xue-han Shen, Wei-xun Chen, Xi Ai, Chao Leng, Bin-yong Liang, Ya-jie Shao
Summary: This study aimed to investigate the relationship between metastatic human hepatocellular carcinoma (HCC) and the dysregulation of MicroRNA-188-5p (miR-188) by using cell lines. The results showed that miR-188 was decreased in metastatic HCC cells compared to normal hepatic cells and non-invasive cell lines. Furthermore, it was found that miR-188 inhibits the proliferation and migration of metastatic HCC cells by targeting FOXN2.
Article
Oncology
Wenping Song, Weijiang Yu, Ding Li, Cheng Cheng, Xuan Wu, Jinhua Chen, Wenzhou Zhang
Summary: This study reveals the important role of ZIC5 in hepatocellular carcinoma, as it promotes the proliferation, migration, and invasion of HCC cells through upregulating COL1A1. The findings suggest an intrinsic link between ZIC5 and COL1A1, providing new research ideas for subsequent HCC studies.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Yalan Deng, Liqing Lu, Xujun Liang, Jingzhi Li, Dandan Zhu, Huichao Huang, Ye Zhang, Xiangqian Zhang, Yongheng Chen, Xiaojin Liu, Ying Fu
Summary: This study reveals that NNAT is significantly downregulated in hepatocellular carcinoma (HCC), and its downregulation is associated with tumor growth and patient prognosis. The decreased expression of NNAT in HCC is induced by hypermethylation of CpG islands in the promoter region, and hypermethylation is correlated with overall survival of HCC. Moreover, NNAT overexpression inhibits HCC cell proliferation by dysregulating the PI3K-Akt signaling pathway.
Review
Biology
Riccardo Nevola, Giovanni Tortorella, Valerio Rosato, Luca Rinaldi, Simona Imbriani, Pasquale Perillo, Davide Mastrocinque, Marco La Montagna, Antonio Russo, Giovanni Di Lorenzo, Maria Alfano, Maria Rocco, Carmen Ricozzi, Klodian Gjeloshi, Ferdinando Carlo Sasso, Raffaele Marfella, Aldo Marrone, Loreta Anesti Kondili, Nicolino Esposito, Ernesto Claar, Domenico Cozzolino
Summary: Significant gender disparities exist in the incidence of hepatocellular carcinoma (HCC), which can be attributed to the different distribution of risk factors and the actions of sex hormones. Accurate knowledge of these disparities can lead to appropriate surveillance strategies and implementation of effective treatment schemes.
Article
Cell Biology
Ye-wei Zhang, Qian Chen, Bo Li, Hai-Yang Li, Xue-Ke Zhao, Yan-yi Xiao, Shu Liu, Shi Zuo
Summary: NAP1L1 is reported to be significantly involved in the carcinogenesis of hepatocellular carcinoma (HCC) by recruiting HDGF/c-Jun, suggesting that it acts as a potential oncogene in HCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Pharmacology & Pharmacy
X-H Liu, L-P Liu, X-M Xu, M. Hua, Q. Kang, A. Li, L. Huang
Summary: This study demonstrated that FOXN2 is downregulated in HCC, while upregulation of FOXN2 significantly inhibits the proliferation and invasion of HCC cells, indicating that FOXN2 may serve as a potential therapeutic monitoring and prognosis biomarker in HCC.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Oncology
Xinmu Zhang, Christina Nadolny, Qiwen Chen, Winifer Ali, Syed F. Hashmi, Ruitang Deng
Summary: This study found that the expression of USP2a is upregulated in hepatocellular carcinoma (HCC) patients and acts as a tumor suppressor gene in HCC pathogenesis. USP2a promotes tumor cell proliferation, resistance, and translation levels through multiple signaling pathways, leading to the occurrence and progression of HCC. The findings provide molecular and pathogenesis bases for developing interventions to treat HCC by targeting USP2a or its downstream pathways.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Deniz Tuemen, Philipp Heumann, Karsten Guelow, Cagla-Nur Demirci, Lidia-Sabina Cosma, Martina Mueller, Arne Kandulski
Summary: This article introduces the molecular pathogenesis of hepatocellular carcinoma (HCC), including various etiological risk factors and related molecular mechanisms of HCC initiation and progression. The treatment sequences for early and advanced tumor stages are summarized according to the Barcelona Clinic Liver Cancer classification system and the algorithm of systemic therapy. Additionally, novel precautional and pre-therapeutic approaches such as therapeutic vaccination, adoptive cell transfer, and non-coding RNA-based therapy are discussed as promising treatment options for HCC.
Review
Biochemistry & Molecular Biology
Yi Lv, Xiujuan Sun
Summary: Hepatocellular carcinoma (HCC) is a common and deadly cancer, and there is a need for new diagnostic markers. miRNA plays an important role in the diagnosis and prognosis of HCC. Changes in miRNA expression are related to HCC cell migration and invasion, and targeting these genes may help with treatment. Additionally, miRNA is involved in angiogenesis, drug resistance, and autophagy. Identifying novel miRNA in HCC tissue may have implications for diagnosis, prognosis, and therapy to improve patient outcomes.
CHEMICAL BIOLOGY & DRUG DESIGN
(2023)
Article
Oncology
Bajin Wei, Hao Chen, Xiaobin Chen, Danjing Guo, Liangjie Hong, Shusen Zheng
Summary: The expression of Sox15 is reduced in hepatocellular carcinoma (HCC) and correlated with prognosis, with its promoter CpG-site methylation predicting a poor outcome. Ectopic expression of Sox15 inhibits cell growth and tumorigenesis in HCC cells. Sox15 acts as a tumor suppressor in HCC by inactivating the Wnt pathway.
FRONTIERS IN ONCOLOGY
(2022)